Homepage

Romain Guyon awarded 2022 Michelson Prize

DPhil student at the Jenner Institute, Romain Guyon is among the researchers who received the 2022 Michelson Prizes: Next Generation Grants, announced by Michelson Medical Research Foundation and Human Immunome Project.

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the city’s two NIHR Biomedical Research Centres (BRC). Professor Helen McShane, Director of the NIHR Oxford BRC and Jenner Investigator said: 'This funding is a recognition of the high calibre work done by our researchers in recent years'.

Malaria booster vaccine continues to meet WHO-specified 75% efficacy goal

Blueprint for new adenovirus-based vaccines within 100 days

Jenner researchers have published a pre-print on how new adenovirus-based vaccines could be produced at large-scale within 100 days of identification of a new virus or variant. They also report an improved manufacturing method which could enable production of 1 billion doses per month. The paper is being submitted to BioRxiv and a peer-reviewed journal, and is temporarily available here:

£50m funding for Poonawalla Vaccines Research Building at Oxford University

The Poonawalla Vaccines Research Building is to be established at Oxford University's Old Road Campus following a £50m funding commitment from Serum Life Sciences, a subsidiary of Serum Institute of India. The building will be a new home for the Jenner Institute. The donation will be the University’s largest ever gift for vaccines research.

Illustration showing how the Ebola virus looks under a microscope

Ebola vaccine to begin human trials

The University of Oxford have begun recruiting for a Phase I trial to test an Ebola vaccine in human volunteers – with the first vaccinations having already taken place.

Vaccine being extracted from vial with a syringe

Vaccine for treating cancer made possible using Oxford COVID vaccine technology

Research from Jenner Institute and Ludwig Institute for Cancer Research has shown the technology behind the Oxford-AstraZeneca COVID-19 vaccine has potential in treating cancer. When tested in mice, the cancer vaccine increased levels of anti-tumour T cells infiltrating tumours and improved efficacy of cancer immunotherapy. Compared to immunotherapy alone, the combination with the vaccine showed a greater reduction in tumour size and improved survival of the mice.

Royal Society Africa Prize winner 2021

The Royal Society Africa Prize 2021 is awarded to Professor George Warimwe, Jenner Investigator, for his work on zoonoses vaccine development, capacity building in Africa, and his innovative research proposal. Professor Warimwe will be awarded a medal and a grant of £15,000 towards his research project at a symposium to be held at a future date.

Vaccine for TB receives a $1.5 million funding boost

The Oxford-run VALIDATE Network, co-directed by Jenner Investigator Prof Helen McShane, has received $1.5 million in funding for its tuberculosis vaccine work from the Bill & Melinda Gates Foundation. An effective vaccine for TB is one of the primary goals of the VALIDATE Network which aims to accelerate vaccine development for complex intracellular pathogens that are often neglected.

Vaccine vials being filled at a biomanufacturing facility

Making a billion doses of vaccine in 18 months: starting with two tablespoons

As the University was planning the first clinical trials for the COVID-19 vaccine, some began to wonder how to supply the vaccine to the world - if it worked. Although Oxford had the capacity to develop a COVID-19 vaccine, and clinical trials might take only a few months, manufacturing ‘at pandemic scale’ would take much longer. A group of University scientists had, however, worked on the problem for some time.

African trial of novel HIV vaccine candidate starts

Professor Tomas Hanke, Professor of Vaccine Immunology at the Jenner Institute, and lead researcher on the trial, said: ‘This highly rational, bioinformatics-assisted, vaccine design addresses the enormous variability of HIV-1 - one of the greatest challenges to the development of an effective vaccine against HIV/AIDS.’

Phase I HIV vaccine trial completes volunteer recruitment in time for World AIDS Day

The Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT) is pleased to announce the completion of recruitment of volunteers for the Phase I HIV-CORE 006 HIV vaccine clinical trial at four sites in Kenya, Uganda and Zambia. Enrolment of the final participants took place today at the KEMRI-Wellcome Trust Research Programme in Kilifi, Kenya, on World AIDS Day.

Vaccine vials in a manufacturing facility

Oxford vaccine reaches two billion dose milestone

University researchers reveal invention of simple manufacturing method which has enabled rapid scale up of vaccine manufacturing in 15 countries around the world, reaching people across seven continents. The approach provides a template for faster and more equitable supply of other vaccines.

T-cell ‘training grounds’ behind robust immune system response seen in adenovirus vaccines

Adenovirus vaccine vectors, such as the ChAdOx1 nCov-19 construct which has risen to prominence as a major vaccine for COVID-19, may generate robust long-term immune system responses, according to scientists from the Universities of Oxford and the Cantonal Hospital St.Gallen, Switzerland.

History of the COVID-19 VACCINE

The Oxford / AstraZeneca COVID-19 vaccine is estimated to have saved more than six million lives – more than any other COVID vaccine, during the first year of use. Read more here

SUPPORT OXFORD’S COVID-19 VACCINE RESEARCH

Funding for Oxford’s COVID-19 vaccine research requires unprecedented speed, scope and ambition. Support from Government, corporations, trusts and foundations will be crucial to the development of a vaccine to combat the new virus. Alongside those traditional sources of funding, philanthropic donations of any size will have real and rapid impact, allowing us to accelerate this time-critical research, and ensure that Oxford’s vaccine solution will be as effective and swift as possible.

If you are interested in supporting this effort, please make a gift here.

Seminars

Latest publications

Rapid-response manufacturing of adenovirus-vectored vaccines
Journal article

Joe CCD. et al, (2023), Nature Biotechnology
Human T follicular regulatory cells with helper and regulatory lineage origins
Journal article

Nguyen Q. and Borrow P., (2023), Nature Reviews Immunology

Health information

In light of the ongoing high rates of COVID-19 nationally, the continuation of the government’s ‘Plan B’ measures, and the latest guidance for higher education providers issued by the Department for Education, the University has agreed the following measures.

Health measures: Face coverings are essential for reducing the spread of COVID-19 and should be worn by all staff and students when moving around University buildings. Members of staff conducting teaching are not required to wear face coverings, to support education delivery. Social distancing is not formally required. However, staff and students are expected to respect each other’s space, using the experience of the last two years.

Working arrangements: Staff who are able to work from home are expected to continue doing so where possible. However, the University is fully open for teaching and research, and buildings remain open and should be accessible to all staff. As such, staff are expected to work on site to support in-person teaching, research and wider University operations where necessary.

Please refer to the University of Oxford Health page for updated health guidance.

Public Engagement

Tweets by The Jenner Institute

COVID-19 Response

Following the recent launch of the government’s Living with COVID-19 guidance, the University has decided that current health measures will remain in place until 26 March in order to avoid disruption during term time.

Protect one another from infection. There is still a high level of transmission of the virus, so the risk of infection remains high. COVID-19 can still pose a serious health threat to certain groups. Be considerate to them by continuing to follow the COVID-19 precautions.

Please continue to take the following actions until 26 March to minimise disruption to University life and academic studies this term:

Test twice a week and if you have symptoms. Remember to report all your LFD results to both the University’s Early Alert Service and the NHS. If you have tested positive for COVID-19 or have symptoms, stay at home and avoid contact with others.
Wear a face covering (unless exempt) when asked. Departments, as well as individual members of teaching staff, can continue to mandate face coverings in teaching and learning environments (unless individuals are exempt). Face coverings are strongly encouraged in libraries and should be worn when moving around University buildings.
Let fresh air in when indoors: keeping windows and doors open increases ventilation and significantly reduces the spread of COVID-19. Please keep them open, particularly in areas which are poorly ventilated or where signs indicate the need to do so.
Get your booster jab as soon as you’re eligible, and get a free flu jab if you can

Please refer to the University of Oxford Health page for updated health guidance.

Cookies on this website